button bars forest bayes pooled summary circles
benefit
(statisticaly significant) 		benefit (nominaly significant, not statitically demonstrated) NS not significant harm statitically significant NS harm not significant low certainty due to bias
 
deaths (OS)progression or deaths (PFS)RFS/DFS

metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)

versus placebo
pembrolizumab alone vs. placebo 1 -46%--32%

metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)

versus sunitinib
atezolizumab alone vs. sunitinib 1 -NS-
atezolizumab plus bevacizumab vs. sunitinib 2 NSNS-
avelumab plus axitinib vs. sunitinib 1 NS-31%-
nivolumab plus cabozantinib vs. sunitinib 1 -40%-49%-
nivolumab plus ipilimumab vs. sunitinib 3 -32%NS-
pembrolizumab plus axitinib vs. sunitinib 1 -47%-31%-
pembrolizumab plus lenvatinib vs. sunitinib 1 -34%-61%-

mRCC - L1 - PDL1 negative metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 negative

versus sunitinib
atezolizumab plus bevacizumab vs. sunitinib 1 -NS-

mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive

versus sunitinib
atezolizumab alone vs. sunitinib 1 -NS-
atezolizumab plus bevacizumab vs. sunitinib 2 NSNS-
avelumab plus axitinib vs. sunitinib 1 -31%-39%-

metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)

versus everolimus
nivolumab alone vs. everolimus 1 -27%NS-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons